{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T22:58:07Z","timestamp":1780095487043,"version":"3.54.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,12]]},"DOI":"10.7759\/cureus.24067","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T12:35:50Z","timestamp":1649766950000},"source":"Crossref","is-referenced-by-count":1,"title":["The Lupus Attack: A Case Report and Literature Review of Myocardial Infarction and Antiphospholipid Syndrome"],"prefix":"10.7759","author":[{"given":"Abhinav","family":"Karan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adefemi","family":"Adeyemo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerolos","family":"Fahmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivasan","family":"Sattiraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients","volume":"46","author":"Cervera R","year":"2002","unstructured":"Cervera R, Piette JC, Font J, et al.. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002, 46:1019-27. 10.1002\/art.10187","journal-title":"Arthritis Rheum"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00941","article-title":"Cardiac manifestations of antiphospholipid syndrome with focus on its primary form","volume":"10","author":"Kolitz T","year":"2019","unstructured":"Kolitz T, Shiber S, Sharabi I, Winder A, Zandman-Goddard G. Cardiac manifestations of antiphospholipid syndrome with focus on its primary form. Front Immunol. 2019, 10:941. 10.3389\/fimmu.2019.00941","journal-title":"Front Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/MCA.0000000000000476","article-title":"Acute myocardial infarction and antiphospholipid antibody syndrome: a systematic review","volume":"28","author":"Nazir S","year":"2017","unstructured":"Nazir S, Tachamo N, Lohani S, et al.. Acute myocardial infarction and antiphospholipid antibody syndrome: a systematic review. Coron Artery Dis. 2017, 28:332-335. 10.1097\/MCA.0000000000000476","journal-title":"Coron Artery Dis"},{"key":"ref4","article-title":"Association between cardiac manifestations and antiphospholipid antibody type and level in a cohort of Serbian patients with primary and secondary antiphospholipid syndrome","volume":"16","author":"Djokovic A","year":"2014","unstructured":"Djokovic A, Stojanovich L, Kontic M, Stanisavljevic N, Radovanovic S, Marisavljevic D. Association between cardiac manifestations and antiphospholipid antibody type and level in a cohort of Serbian patients with primary and secondary antiphospholipid syndrome. Isr Med Assoc J. 2014, 16:162-7.","journal-title":"Isr Med Assoc J"},{"key":"ref5","article-title":"The role of lupus anticoagulant and triple marker positivity as risk factors for rethrombosis in patients with primary antiphospholipid syndrome","volume":"31","author":"Hern\u00e1ndez-Molina G","year":"2013","unstructured":"Hern\u00e1ndez-Molina G, Espericueta-Arriola G, Cabral AR. The role of lupus anticoagulant and triple marker positivity as risk factors for rethrombosis in patients with primary antiphospholipid syndrome. Clin Exp Rheumatol. 2013, 31:382-8.","journal-title":"Clin Exp Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou MG","year":"2019","unstructured":"Tektonidou MG, Andreoli L, Limper M, et al.. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019, 78:1296-304. 10.1136\/annrheumdis-2019-215213","journal-title":"Ann Rheum Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1159\/000177119","article-title":"Successful treatment of acute myocardial infarction by thrombolytic therapy in a patient with primary antiphospholipid antibody syndrome","volume":"87","author":"Ho YL","year":"1996","unstructured":"Ho YL, Chen MF, Wu CC, et al.. Successful treatment of acute myocardial infarction by thrombolytic therapy in a patient with primary antiphospholipid antibody syndrome. Cardiology. 1996, 87:354-7. 10.1159\/000177119","journal-title":"Cardiology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1159\/000338347","article-title":"Long-term outcome of patients with antiphospholipid syndrome who undergo percutaneous coronary intervention","volume":"122","author":"Perl L","year":"2012","unstructured":"Perl L, Netzer A, Rechavia E, et al.. Long-term outcome of patients with antiphospholipid syndrome who undergo percutaneous coronary intervention. Cardiology. 2012, 122:76-82. 10.1159\/000338347","journal-title":"Cardiology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035241","article-title":"A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome","volume":"349","author":"Crowther MA","year":"2003","unstructured":"Crowther MA, Ginsberg JS, Julian J, et al.. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003, 349:1133-8. 10.1056\/NEJMoa035241","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.05.016","article-title":"Management of antithrombotic therapy in atrial fibrillation patients undergoing\u00a0PCI: JACC state-of-the-art review","volume":"74","author":"Capodanno D","year":"2019","unstructured":"Capodanno D, Huber K, Mehran R, et al.. Management of antithrombotic therapy in atrial fibrillation patients undergoing\u00a0PCI: JACC state-of-the-art review. J Am Coll Cardiol. 2019, 74:83-99. 10.1016\/j.jacc.2019.05.016","journal-title":"J Am Coll Cardiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/90436-the-lupus-attack-a-case-report-and-literature-review-of-myocardial-infarction-and-antiphospholipid-syndrome","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:37:47Z","timestamp":1707507467000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/90436-the-lupus-attack-a-case-report-and-literature-review-of-myocardial-infarction-and-antiphospholipid-syndrome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,12]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.24067","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,12]]}}}